TransMedics Group experienced a 20% price increase over the last month. While the market has generally risen by about 5% in the past week and 4% over the past year, the company's performance stood out ...

TransMedics Group (NASDAQ: TMDX) once ranked among the hottest healthcare stocks around. Shares of the medical technology company delivered a gain of more than ninefold between the beginning of 2022 ...

On Wednesday, Needham maintained its Hold rating on TransMedics Group (NASDAQ:TMDX) shares, which currently trades at $70.79. According to InvestingPro data, the company has demonstrated remarkable ...

Been wondering if TransMedics Group stock is a smart buy or just getting overhyped? You are not alone, especially with all the chatter about its valuation lately. Over the last week, the stock shot up ...

Shares of organ transplant innovator TransMedics Group (NASDAQ: TMDX) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence. TransMedics was the target of an ...

Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion ...

Renaissance Investment Management, an investment management company, released its Q4 2024 “Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. The Russell 2000 ...

ANDOVER, Mass. - TransMedics Group, Inc. (NASDAQ:TMDX), a medical technology company with a market capitalization of $4.17 billion and impressive year-to-date stock gains of 96%, announced today a ...

TransMedics reported second-quarter financial results that were considerably better than most investors had anticipated. On the sales front, gains of 38% to $157 million were healthily higher than ...

In its latest quarter, TransMedics reported solid gains in revenue and saw net income nearly triple from year-ago levels. TransMedics increased its full-year 2025 sales outlook. Co-founder/CEO Waleed ...